ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Advances in stem cell research for the treatment of primary hypogonadism
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 209440" data-attributes="member: 13851"><p><strong>Fig. 4 | <u>Applications of stem cell-derived, Leydig-like cells for the study and treatment of primary hypogonadism</u>. <u>a</u> | Leydig-like cells (LLCs) derived from stem cells of healthy men can be used to study Leydig cell development in vitro. A comparison of successful induction strategies used in rodents and humans might improve understanding of why differentiation of human Leydig cells differs from that in other species. <u>b</u> | LLCs derived from stem cells of hypogonadal men can be used for disease modeling through the manipulation of genetic factors, environmental exposures, and lifestyle. Candidate genes that might cause primary hypogonadism can be manipulated in healthy stem cells, which are further differentiated into LLCs to provide a model for the investigation of the pathophysiology of male hypogonadism. <u>c</u> | LLCs derived from patient-specific stem cells could undergo gene editing to correct genetic mutations and be transplanted back to patients to ameliorate the symptoms of primary hypogonadism. <u>d</u> | Drugs can be tested on LLCs derived from men with primary hypogonadism. Different patients with primary hypogonadism might show different responses to the same drug. Only the patient whose stem cell-derived LLCs are responsive to the drugs will receive the treatment with these drugs. Those patients whose stem cell-derived LLCs show weak or no response to drugs will not adopt such treatment. This approach can be used to select appropriate drugs and to limit unnecessary adverse effects for individual patients. </strong></p><p><strong>[ATTACH=full]16863[/ATTACH]</strong></p><p><strong>[ATTACH=full]16866[/ATTACH]</strong></p><p><strong></strong></p><p><strong></strong></p></blockquote><p></p>
[QUOTE="madman, post: 209440, member: 13851"] [B]Fig. 4 | [U]Applications of stem cell-derived, Leydig-like cells for the study and treatment of primary hypogonadism[/U]. [U]a[/U] | Leydig-like cells (LLCs) derived from stem cells of healthy men can be used to study Leydig cell development in vitro. A comparison of successful induction strategies used in rodents and humans might improve understanding of why differentiation of human Leydig cells differs from that in other species. [U]b[/U] | LLCs derived from stem cells of hypogonadal men can be used for disease modeling through the manipulation of genetic factors, environmental exposures, and lifestyle. Candidate genes that might cause primary hypogonadism can be manipulated in healthy stem cells, which are further differentiated into LLCs to provide a model for the investigation of the pathophysiology of male hypogonadism. [U]c[/U] | LLCs derived from patient-specific stem cells could undergo gene editing to correct genetic mutations and be transplanted back to patients to ameliorate the symptoms of primary hypogonadism. [U]d[/U] | Drugs can be tested on LLCs derived from men with primary hypogonadism. Different patients with primary hypogonadism might show different responses to the same drug. Only the patient whose stem cell-derived LLCs are responsive to the drugs will receive the treatment with these drugs. Those patients whose stem cell-derived LLCs show weak or no response to drugs will not adopt such treatment. This approach can be used to select appropriate drugs and to limit unnecessary adverse effects for individual patients. [ATTACH type="full"]16863[/ATTACH] [ATTACH type="full"]16866[/ATTACH] [/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Advances in stem cell research for the treatment of primary hypogonadism
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top